Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pediatric Oncology Advances Could Prompt More FDA-Required Studies

Executive Summary

Findings being presented at ASCO next month could signify major increase in targets relevant to pediatric oncology, meaning sponsors should prepare for more US FDA-required studies under the RACE for Children legislation.


Related Content

Pediatric Cancer: US FDA Will Take ‘Rational’ Approach To Requiring Combination Studies
Tissue-Agnostic Cancer Treatments: Can US FDA-Approved Diagnostics Limit Access?
Oncology Sponsors Getting A Jump On Pediatric Study Requirements, US FDA Says
Roche’s EU Accelerated Assessment Bid For Tumor Agnostic Entrectinib Backfires
Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy
FDA Nod For Loxo/Bayer Tissue Agnostic Drug Marks Paradigm Shift In Cancer
Plenty Of Potential For Roche's Entrectinib Despite Lack Of ESMO Enthusiasm
Roche’s Entrectinib Differentiates Itself From NSCLC Competitors With CNS Data
Pediatric Cancer Studies: US FDA Promises Flexible Approach On Requirements
Genomics-Driven Trials Built To Be Fast And Flexible


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts